Manila Bulletin
FDA okays Chinese firm's vaccine clinical trials
The Philippine FDA has approved Clover Biopharmaceuticals' application for Phase III clinical trials of its COVID-19 vaccine in the country.
This approval follows earlier clearances from the Department of Science and Technology - Vaccine Expert Panel (DOST-VEP) and the Single Joint Ethics Review Board (SJREB).
Clover Biopharmaceuticals is the second vaccine developer to receive approval for clinical trials in the Philippines, after Belgium-based Janssen Pharmaceuticals.
Janssen Pharmaceuticals is expected to begin its trials this month.
The FDA is still awaiting necessary documents from China's Sinovac Biotech for a decision on its vaccine clinical trial application.
Additionally, Russia's Gamaleya Research Institute has submitted an application for emergency use authorization for its COVID-19 vaccine.
Topics in this story
Explore more stories about these topics.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
Chinese pharmaceutical company Sinovac has submitted an application for emergency use authorization (EUA) to the Philippine Food and Drug Administration (FDA).
Read more →
British pharmaceutical firm AstraZeneca has applied for emergency use authorization (EUA) for its COVID-19 vaccine in the Philippines, marking the second such application after Pfizer.
+1
Read more →
The Philippine Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to the Pfizer-BioNTech COVID-19 vaccine, making it the first to receive such approval in the country.
+2
Read more →
Russia's Gamaleya Research Institute has applied for an emergency use authorization (EUA) for its Sputnik V vaccine in the Philippines.
Read more →
The Philippines has secured 30 million doses of the Novavax COVID-19 vaccine, with initial supplies expected to arrive in the 3rd quarter of 2021.
Read more →